Pomerantz LLP

Please review this complaint. Click to Contact Us about joining this ACTION >>

Questions? Ask Us

Halozyme Therapeutics, Inc. 

Pomerantz LLP is investigating claims on behalf of investors of Halozyme Therapeutics, Inc. ("Halozyme" or the "Company").  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Halozyme and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

On November 26, 2018, Halozyme issued a press release announcing "that prior to data analysis, the [U.S. Food and Drug Administration] has agreed to Halozyme's request to change the primary endpoint of the HALO-301 study to the single primary endpoint of overall survival (OS).  As a result, the previously planned interim analysis will not be conducted." 

Following this announcement, Halozyme's stock price fell $1.24 per share, or 7.42%, to close at $15.47 per share on November 27, 2018.